Evidence map›Paper›PMID 32767721›Full record

ArticleAnnals of clinical and translational neurology2020

Association of MAPT subhaplotypes with clinical and demographic features in Parkinson's disease.

Angela B Deutschlander, Takuya Konno, Alexandra I Soto-Beasley, Ronald L Walton, Jay A van Gerpen, Ryan J Uitti, Michael G Heckman, Zbigniew K Wszolek, Owen A Ross

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Genetic meta-analysis of levodopa induced dyskinesia in Parkinson's disease.medRxiv : the preprint server for health sciences · 2023
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Angela B DeutschlanderDepartment of Neurology, Mayo Clinic, Jacksonville, Florida.
Takuya KonnoDepartment of Neurology, Mayo Clinic, Jacksonville, Florida.
Alexandra I Soto-BeasleyDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida.
Ronald L WaltonDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida.
Jay A van GerpenDepartment of Neurology, Mayo Clinic, Jacksonville, Florida.
Ryan J UittiDepartment of Neurology, Mayo Clinic, Jacksonville, Florida.
Michael G HeckmanDivision of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, Florida.
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, Florida.
Owen A RossDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida.ORCID 0000-0003-4813-756X
Jacksonville College · US

Funding

Utilization of proteomics and lipidomics to identify modifiers of LBDU54NS110435 · NINDS · MAYO CLINIC JACKSONVILLE · PI MCLEAN, PAMELA J · 2019 to 2023
$14.5M
Project 2: Identifying genes and Pathways that impact Tau Toxicity in FTDU54NS100693 · NINDS · MAYO CLINIC JACKSONVILLE · PI DICKSON, DENNIS WILLIAM · 2016 to 2020
$6.2M
Understanding the role of MAPT in Parkinsonian disordersR01NS078086 · NINDS · MAYO CLINIC JACKSONVILLE · PI ROSS, OWEN A · 2012 to 2016
$1.7M
Congressionally Directed Medical Research Programs W81XWH-17-1-0249NINDS NIH HHS NS100693NINDS NIH HHS NS110435NINDS NIH HHS R01 NS078086NINDS NIH HHS R01 NS78086NINDS NIH HHS U54 NS100693NINDS NIH HHS U54 NS110435
6 · The paper itself

Abstract

objectiveTo determine whether distinct microtubule-associated protein tau MAPT H1 subhaplotypes are associated with clinical and demographic features in Parkinson's disease.

methodsA retrospective cohort study included 855 unrelated Caucasian patients with Parkinson's disease who were seen by Movement Disorder specialists at the Mayo Clinic Florida between 1998 and 2016. The primary outcome measures were specific demographic and clinical features of Parkinson's disease, including age at onset, disease progression, survival, motor signs, dementia, dystonia, dyskinesia, autonomic dysfunction, impulse control disorder, psychiatric features, REM sleep behavior disorder, restless legs syndrome, and Parkinson's disease subtype. Specific clinical features were measured at the initial visit and most recent visit. These outcomes were assessed for association with MAPT H1 subhaplotypes, which were defined by six haplotype tagging variants.

resultsMedian onset age was 64 years (range: 22-94 years); 548 (64%) of patients were male. Significant associations (P < 0.0029) were observed between MAPT H1b and orthostatic hypotension (OR = 1.72, P = 0.001); between H1j and rest tremor (OR = 0.15; P < 0.001) as well as REM sleep behavior disorder (OR = 3.87, P < 0.001); between H1r and bradykinesia (OR = 0.11; P < 0.001); and between H1v and restless legs syndrome (OR = 4.02, P = 0.002).

interpretationFour MAPT H1 subhaplotypes, but not the H2 haplotype, were significantly associated with specific clinical features in Parkinson's disease. MAPT haplotypic structure may explain some of the phenotypic variability in disease. Replication of our findings will be critical to fully resolve the Parkinson's disease risk association signal at Chr17q21.

Indexed as

AdultAgedAged, 80 and overAge of OnsetFemaleGenetic Association StudiesHaplotypesHumansMaleMiddle AgedParkinson DiseaseRetrospective Studiestau ProteinsMAPT protein, humantau Proteins

Identifiers

PMID32767721
PMCPMC7480915
OpenAlexW3047954203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.